GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES

GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES

Show other versions (3)

The Task Force on Diabetes and Cardiovascular diseases of the European Society of Cardiology and of the European Association for the Study of Diabetes.European Heart Journal (2007) 28, 88-136.

Bibliographic Details
Main Authors:	L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, K. Malmberg, S. Priori, J. Ostergren, J. Tuomilehto, I. Thrainsdottir
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-12-01
Series:	Рациональная фармакотерапия в кардиологии
Online Access:	https://www.rpcardio.online/jour/article/view/518

Similar Items

GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
by: L. Ryden, et al.
Published: (2015-12-01)

GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
by: L. Ryden, et al.
Published: (2015-12-01)

GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
by: L. Ryden, et al.
Published: (2015-12-01)

ESC GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES DEVELOPED IN COLLABORATION WITH THE EASD
by: Lars Rydén, et al.
Published: (2014-03-01)

COMMENTS ON GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
by: An. A. Alexandrov
Published: (2015-12-01)

COMMENTS ON GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
by: An. A. Alexandrov
Published: (2015-12-01)

Type 2 Diabetes and Metabolic Syndrome Patients: Management Recommendations for Reducing Cardiovascular Risk
by: Hobbs, R, et al.
Published: (2009)

COMMENTS ON GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES ESC-EASD 2007
by: M. V. Shestakova
Published: (2015-12-01)

COMMENTS ON GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES ESC-EASD 2007
by: M. V. Shestakova
Published: (2015-12-01)

Cardiovascular risk management: 6 Patients with type 2 diabetes and metabolic syndrome - Management recommendations for reducing cardiovascular risk
by: Hobbs, F, et al.
Published: (2011)

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
by: Coleman, R, et al.
Published: (2019)

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Charlton-Menys, V, et al.
Published: (2009)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Colhoun, H, et al.
Published: (2005)

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)
by: Charlton-Menys, V, et al.
Published: (2009)

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
by: Antonio Ceriello, et al.
Published: (2023-10-01)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
by: Colhoun, H, et al.
Published: (2004)

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Colhoun, H, et al.
Published: (2009)

Guidelines on diabetes, pre-diabetes and cardiovascular diseases. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), 2007
by: Editorial team Diabetes Mellitus
Published: (2008-03-01)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Raikou, M, et al.
Published: (2007)

Status report of lipid-lowering trials in diabetes.
by: Betteridge, D, et al.
Published: (2000)

Diabetic Foot Australia guideline on footwear for people with diabetes
by: Jaap J. van Netten, et al.
Published: (2018-01-01)

Heart failure in diabetes: From an increased risk to a treatment target
by: Eberhard Standl
Published: (2018-11-01)

The “Common Soil Hypothesis” Revisited—Risk Factors for Type 2 Diabetes and Cardiovascular Disease
by: Lilian Fernandes Silva, et al.
Published: (2021-10-01)

Diabetes on a cardiovascular ward: adherence to current recommendations.
by: Bethel, M, et al.
Published: (2004)

Cardiovascular risk management in people with type 1 diabetes: performance using three guidelines
by: Erwin Birnie, et al.
Published: (2022-07-01)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
by: Colhoun, H, et al.
Published: (2002)

The Evaluation of Cardiovascular Risk in Diabetic Patients
by: Kosirova S., et al.
Published: (2022-04-01)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
by: Thomason, M, et al.
Published: (2004)

The effectiveness and cost of single and multi-factorial cardiovascular risk factor modification to guideline targets in type 2 diabetes
by: Prescott, A, et al.
Published: (2012)

The effectiveness and cost of single and multi-factorial cardiovascular risk factor modification to guideline targets in type 2 diabetes.
by: Prescott, A, et al.
Published: (2012)

Corrections needed to 2016 ESC and AHA guidelines on heart failure.
by: Rydén, L, et al.
Published: (2017)

Australian guideline on wound classification of diabetes‐related foot ulcers: part of the 2021 Australian evidence‐based guidelines for diabetes‐related foot disease
by: Emma J. Hamilton, et al.
Published: (2021-01-01)

Prevalence and projections of diabetes and pre-diabetes in adults in Sri Lanka--Sri Lanka Diabetes, Cardiovascular Study (SLDCS).
by: Katulanda, P, et al.
Published: (2008)

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
by: Holman, R, et al.
Published: (2017)

EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021)
by: I. E. Chazova, et al.
Published: (2021-05-01)

Effect of nateglinide on the incidence of diabetes and cardiovascular events.
by: Holman, R, et al.
Published: (2010)

Effect of valsartan on the incidence of diabetes and cardiovascular events.
by: McMurray, J, et al.
Published: (2010)

Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
by: Tonkin, A, et al.
Published: (2012)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)
by: Hitman, G, et al.
Published: (2005)

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes
by: Jessica A. Regan, et al.
Published: (2023-09-01)